Tamoxifen citrate
英文名称: Tamoxifen citrate
型号:null    产品货号: IHR1032-0050MG
价格:请致电:010-57128832,18610462672
品牌: gene operation

 IHR1032-Tamoxifen citrate

TAMOXIFEN CITRATE(Nolvadex), >99 %

【英文同义名】:TMX citrate, ICI-46474, Nolvadex® , Istubal®, Valodex®, Tamodex®

【中文同义名】:塔莫西酚

订购信息:(原装进口,常备现货)

 

产品名称

产品货号

目录价(元)

Gene Operation

TAMOXIFEN CITRATE(Nolvadex) (estrogen receptor  modulator)

IHR1032-0050MG

50MG

369

IHR1032-0100MG

100MG

719

IHR1032-0500MG

500MG

2139

产品描述

Tamoxifen citrate (同义名: TMX citrate, ICI-46474, Nolvadex® , Istubal®, Valodex®, Tamodex®

Tamoxifen的枸橼酸盐,是选择性Estrogen receptorER)(雌***受体)调控剂。Tamoxifen在乳腺中表现出拮抗功能,而在其它组织,如子宫内膜中是一种激动剂。Tamoxifen抑制SR31747与重组mSIhis的结合,IC50分别为1.9 nM3.6 nMTamoxifen选择性抑制哺乳动物SI细胞中的甾醇生成[1]Tamoxifen提高乳腺癌中VEGF mRNA表达,在体内实验中,却降低MCF-7移植瘤小鼠中细胞外VEGF水平。Tamoxifen辅助治疗雌***依赖的乳腺癌,可以阻止肿瘤细胞转移,并提高病人存活[2]Tamoxifen还可以降低女性血清中LDL胆固醇,已经用于女性乳腺癌的治疗。

靶点

靶点

ER

IC50(半数有效浓度)

 

化学特性

Cas No.: 54965-24-1

分子量: 563.64

分子式: C26H29NO·C6H8O7

纯度: >99% 

同义名: TMX citrate, ICI-46474, Nolvadex® , Istubal®, Valodex®, Tamodex®

化学名:(Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine citrate

外观: 白色结晶粉末

溶解: 溶于DMSO(up to 100 mg/mL)

保存:3 -20 粉末

储存液配制

储存液 (1 ml DMSO体系)

1 mM

5 mM

10 mM

25 mM

50 mM

100 mM

质量(mg)

0.5636

2.8182

5.6364

14.0910

28.1820

56.3640

结构式

使用浓度(仅作参考)

Tamoxifen citrate的具体使用浓度请参考相关文献,并根据自身实验条件(如实验目的,细胞种类,培养特性等)进行摸索和优化。

参考文献

[1] Clarke M, et al. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists Collaborative Group. Lancet. 351(9114):1451-67 (1998).

[2] Johnson MD, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl ***, a novel active metabolite of ***. Breast Cancer Research and Treatment 85(2):151-9 (2004).

[3] Gottardis MM, et al. Contrasting actions of *** on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48(4):812-5 (1988).

[4] Love RR, et al. Effects of *** on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 326(13):852-6 (1992).

[5] Guetta V, et al. Effects of the antiestrogen *** on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol. 76(14):1072-3 (1995).

[6] Thomas P, et al. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology. 146(2):624-32 (2005).

[7] OBrian CA, et al. Inhibition of protein kinase C by ***. Cancer Res. 45(6):2462-5 (1985).